1.91
price up icon8.52%   0.15
after-market 시간 외 거래: 2.00 0.09 +4.71%
loading
전일 마감가:
$1.76
열려 있는:
$1.78
하루 거래량:
9.88M
Relative Volume:
2.96
시가총액:
$314.98M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-95.50
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
-18.72%
1개월 성능:
-20.42%
6개월 성능:
+139.86%
1년 성능:
+60.50%
1일 변동 폭
Value
$1.775
$1.96
1주일 범위
Value
$1.72
$2.4275
52주 변동 폭
Value
$0.40
$3.095

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
명칭
Cytomx Therapeutics Inc
Name
전화
650.515.3185
Name
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
직원
121
Name
트위터
@cytomxinc
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
CTMX's Discussions on Twitter

CTMX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
1.91 290.25M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.79 100.07B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.41 59.99B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
448.91 58.03B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
653.83 39.93B 3.06B 1.28B -614.78M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
321.36 36.82B 3.81B -644.79M -669.77M -6.24

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-31 개시 Oppenheimer Outperform
2025-05-15 업그레이드 H.C. Wainwright Neutral → Buy
2025-04-14 재개 Piper Sandler Overweight
2024-05-28 업그레이드 Piper Sandler Neutral → Overweight
2024-05-09 업그레이드 Wedbush Neutral → Outperform
2024-05-06 업그레이드 Jefferies Hold → Buy
2024-04-22 업그레이드 JP Morgan Underweight → Neutral
2022-11-14 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-07-07 다운그레이드 Jefferies Buy → Hold
2022-07-07 다운그레이드 Mizuho Buy → Neutral
2022-07-07 다운그레이드 Piper Sandler Overweight → Neutral
2022-07-07 다운그레이드 Wedbush Outperform → Neutral
2022-06-24 개시 BMO Capital Markets Outperform
2022-01-18 업그레이드 Barclays Underweight → Overweight
2021-11-15 개시 BTIG Research Buy
2021-05-28 다운그레이드 Barclays Equal Weight → Underweight
2021-03-29 개시 JP Morgan Overweight
2021-03-23 업그레이드 Jefferies Hold → Buy
2020-09-22 다운그레이드 Guggenheim Buy → Neutral
2020-06-01 다운그레이드 Jefferies Buy → Hold
2020-05-14 재확인 H.C. Wainwright Buy
2020-03-24 업그레이드 Wedbush Neutral → Outperform
2020-03-04 개시 Barclays Equal Weight
2019-11-20 개시 Guggenheim Buy
2019-11-11 다운그레이드 Wedbush Outperform → Neutral
2019-06-13 개시 Mizuho Buy
2019-05-14 개시 Cantor Fitzgerald Overweight
2019-03-11 개시 Barclays Overweight
2018-11-26 개시 Piper Jaffray Overweight
2018-10-15 개시 Goldman Neutral
2018-09-13 개시 H.C. Wainwright Buy
2018-06-01 개시 SunTrust Buy
2018-01-05 개시 Citigroup Buy
2017-09-08 개시 Wedbush Outperform
2017-03-27 개시 H.C. Wainwright Buy
2017-03-02 개시 Instinet Buy
2017-01-03 다운그레이드 Oppenheimer Outperform → Perform
2015-11-02 개시 Oppenheimer Outperform
모두보기

Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스

pulisher
09:09 AM

What makes CytomX Therapeutics Inc. stock price move sharplyShare Buyback & High Return Trade Guides - sundaytimes.kr

09:09 AM
pulisher
08:17 AM

CytomX's High-Risk, High-Reward ADC Strategy: Can CX-2051 Overcome Safety Hurdles and Deliver Value? - AInvest

08:17 AM
pulisher
08:03 AM

Published on: 2025-08-15 21:04:24 - sundaytimes.kr

08:03 AM
pulisher
07:46 AM

CytomX to continue Phase I ADC trial despite patient death - Yahoo Finance

07:46 AM
pulisher
05:03 AM

CytomX Therapeutics Soars 10.23% on Clinical Trial Progress - AInvest

05:03 AM
pulisher
Aug 14, 2025

RSI Suggests Rebound May Be Near in CytomX Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Reports - metal.it

Aug 14, 2025
pulisher
Aug 14, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

Cancer patient dies in clinical trial, drugmaker's stock falls, but the study goes on - The Business Journals

Aug 14, 2025
pulisher
Aug 14, 2025

Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st

Aug 14, 2025
pulisher
Aug 14, 2025

Slammed 26% CytomX Therapeutics, Inc. (NASDAQ:CTMX) Screens Well Here But There Might Be A Catch - 富途牛牛

Aug 14, 2025
pulisher
Aug 13, 2025

CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com Australia

Aug 13, 2025
pulisher
Aug 13, 2025

Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus

Aug 13, 2025
pulisher
Aug 13, 2025

CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener

Aug 13, 2025
pulisher
Aug 13, 2025

CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan

Aug 13, 2025
pulisher
Aug 12, 2025

Published on: 2025-08-13 07:49:54 - sundaytimes.kr

Aug 12, 2025
pulisher
Aug 11, 2025

CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks

Aug 11, 2025
pulisher
Aug 10, 2025

CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest

Aug 10, 2025
pulisher
Aug 10, 2025

CytomX Therapeutics Inc. Inches Above Key Support — Safe to HoldMarket Momentum Signal Generator Shows Trends - beatles.ru

Aug 10, 2025
pulisher
Aug 09, 2025

CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest

Aug 09, 2025
pulisher
Aug 08, 2025

CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha

Aug 08, 2025
pulisher
Aug 08, 2025

CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com

Aug 08, 2025
pulisher
Aug 08, 2025

CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Aug 08, 2025
pulisher
Aug 08, 2025

CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Aug 08, 2025
pulisher
Aug 08, 2025

CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus

Aug 08, 2025
pulisher
Aug 08, 2025

CytomX Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics Posts Q2 2025 Financials, Announces Positive CX-2051 Results, and Extends Runway to Q2 2027. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Reports Q2 Revenue Drop of 26%, Narrows Operating Losses Amid Pipeline Progress - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX (CTMX) Q2 Revenue Drops 26% - Nasdaq

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics reports Q2 EPS 0c, consensus (6c) - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics Announces Second Quarter 2025 Financial Resu - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics Inc Q2 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $18.7 Million - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics files $250M mixed securities shelf - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics Q2 Revenue Beats Estimates, Earnings Up 23.5M - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Therapeutics beats Q2 revenue estimates - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

CytomX Earnings: Breakthrough Colorectal Cancer Drug Shows Promise as Company Raises $100M - Stock Titan

Aug 07, 2025
pulisher
Aug 06, 2025

CytomX Therapeutics to Report Second Quarter 2025 Financial Resu - GuruFocus

Aug 06, 2025
pulisher
Aug 05, 2025

CytomX Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Aug 05, 2025
pulisher
Aug 04, 2025

Oppenheimer Initiates Coverage on CytomX Therapeutics (NASDAQ:CTMX) - MarketBeat

Aug 04, 2025

Cytomx Therapeutics Inc (CTMX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$36.35
price down icon 0.41%
$86.92
price up icon 0.88%
$26.69
price up icon 0.91%
$127.80
price up icon 0.04%
$113.52
price up icon 0.73%
biotechnology ONC
$321.36
price up icon 3.77%
자본화:     |  볼륨(24시간):